Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial – LUNG CANCER

-Ares, LP; Goto, Y; Lim, DWT; Halmos, B; Cho, BC; Cobo, M; Larriba, JLG; Zhou, CC; Demedts, I; Atmaca, A; Baka, S; Mookerjee, B; Portella, S; Zhu, ZW; Wu, JC; Demanse, D; Dharan, B; Reck, M – 2024 – 10.1016/j.lungcan.2023.107451

Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer – JOURNAL FOR IMMUNOTHERAPY OF CANCER

Molina-Alejandre, M; Perea, F; Calvo, V; Martinez-Toledo, C; Nadal, E; Sierra-Rodero, B; Casarrubios, M; Casal-Rubio, J; Martinez-Martí, A; Insa, A; Massuti, B; Viteri, S; Aranda, IB; Rodriguez-Abreu, D; de Castro, J; Martínez, JM; Cobo, M; Wistuba, II; Parra, ER;...

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial – JOURNAL OF CLINICAL ONCOLOGY

Tan, DSW; Felip, E; de Castro, G; Solomon, BJ; Greystoke, A; Cho, BC; Cobo, M; Kim, TM; Ganguly, S; Carcereny, E; Paz-Ares, L; Bennouna, J; Garassino, MC; Schenker, M; Kim, SW; Brase, JC; Bury-Maynard, D; Passos, VQ; Deudon, S; Dharan, B; Song, YB; Caparica, R;...